Search clinical trials for: PD-1 antibody

Total 16369 results

Fudan University

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Beijing Tongren Hospital

Not yet recruiting

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Surgery | PD-1

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Advanced Malignant Tumors

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Eye & ENT Hospital of Fudan University

Not yet recruiting

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Sun Yat-sen University

Recruiting

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

Colorectal Cancer Metastatic | MSS

China
Zhujiang Hospital

Not yet recruiting

Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study

Hepatocellular Carcinoma Non-resectable
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Uterine Cervical Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Pfizer

Withdrawn

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

Poland, United States
Chinese PLA General Hospital

Unknown

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer... and other collaborators

Recruiting

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Lynch Syndrome

China
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

Multiple Primary Lung Cancers

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
Xuhua Duan

Recruiting

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

NSCLC

China
Academisch Medisch Centrum - Universiteit van Amsterdam...
Agenus Inc.; Dutch Cancer Society

Not yet recruiting

ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study (ITHACA)

Cervical Cancer

Netherlands
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Colorectal Cancer

China
Shixiu Wu

Recruiting

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Pancreatic Cancer

China
Sun Yat-sen University
Fudan University; Liaoning Tumor Hospital & Institute

Active, not recruiting

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Colorectal Carcinoma

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Unknown

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Shanghai Zhongshan Hospital

Unknown

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Sun Yat-sen University

Completed

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Gastric Cancer Stage IV | EBV

China
Beijing Friendship Hospital

Recruiting

DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH

Hemophagocytic Lymphohistiocytosis

China
Beijing 302 Hospital

Recruiting

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer

Endometrial Cancer

China
Adagene (Suzhou) Limited

Terminated

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Solid Tumor | Non Hodgkin Lymphoma

China
Sun Yat-sen University

Unknown

A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer

Colorectal Cancer Stage III

China
Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
Zhejiang University

Recruiting

Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients (CISLD-8)

Hepatocellular Carcinoma

China
The First Hospital of Jilin University

Completed

Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Unknown

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China

3

Subscribe